July 16 (Reuters) - U.S. Fda: :Fda Will Not Object To Distribution Of Chantix (Varenicline) With Nitrosamine Below The Interim Acceptable Intake Limit.Fda - Will Not Object To Distribution Of Varenicline Tablets With N-Nitroso-Varenicline Below Interim Acceptable Intake Limit Of 185 Ng Per Day.Fda - Continues To Evaluate Data And May Update The Interim Acceptable Limit Of Nitrosamine In Varenicline Tablets In The Future.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com;)).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments